Segment, Geographic and Other Revenue Information - Revenues By Products (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 27, 2020	Sep. 29, 2019	Sep. 27, 2020	Sep. 29, 2019
Revenue from External Customer [Line Items]
Revenues		$ 12,131	$ 12,680	$ 35,961	$ 39,062
Biopharma, Upjohn And Consumer Healthcare Segments [Member]
Revenue from External Customer [Line Items]
Revenues		12,131	12,680	35,961	39,062
Biopharma, Upjohn And Consumer Healthcare Segments [Member] | Total Alliance revenues [Member]
Revenue from External Customer [Line Items]
Revenues		1,250	1,141	4,036	3,418
Biopharma, Upjohn And Consumer Healthcare Segments [Member] | Total Biosimilars [Member]
Revenue from External Customer [Line Items]
Revenues	[1]	424	236	1,001	632
Biopharma, Upjohn And Consumer Healthcare Segments [Member] | Total Sterile Injectable Pharmaceuticals [Member]
Revenue from External Customer [Line Items]
Revenues	[2]	1,195	1,248	3,839	3,703
Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		10,215	9,952	30,017	28,429
Internal Medicine [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	2,085	2,128	6,695	6,508
Internal Medicine [Member] | Biopharma [Member] | Eliquis [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	1,114	1,025	3,686	3,121
Internal Medicine [Member] | Biopharma [Member] | Chantix / Champix [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	223	276	728	825
Internal Medicine [Member] | Biopharma [Member] | Premarin family [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	168	182	471	542
Internal Medicine [Member] | Biopharma [Member] | BMP2 [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	70	66	197	212
Internal Medicine [Member] | Biopharma [Member] | Toviaz [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	59	61	183	186
Internal Medicine [Member] | Biopharma [Member] | All other Internal Medicine [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	451	517	1,429	1,621
Oncology [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		2,761	2,350	7,843	6,547
Oncology [Member] | Biopharma [Member] | Ibrance [Member]
Revenue from External Customer [Line Items]
Revenues		1,357	1,283	3,955	3,677
Oncology [Member] | Biopharma [Member] | Xtandi alliance revenues [Member]
Revenue from External Customer [Line Items]
Revenues		266	225	741	594
Oncology [Member] | Biopharma [Member] | Sutent [Member]
Revenue from External Customer [Line Items]
Revenues		202	224	616	704
Oncology [Member] | Biopharma [Member] | Inlyta [Member]
Revenue from External Customer [Line Items]
Revenues		195	139	559	316
Oncology [Member] | Biopharma [Member] | Xalkori [Member]
Revenue from External Customer [Line Items]
Revenues		122	130	409	385
Oncology [Member] | Biopharma [Member] | Bosulif [Member]
Revenue from External Customer [Line Items]
Revenues		111	90	324	267
Oncology [Member] | Biopharma [Member] | Retacrit [Member]
Revenue from External Customer [Line Items]
Revenues	[1]	102	64	278	147
Oncology [Member] | Biopharma [Member] | Lorbrena [Member]
Revenue from External Customer [Line Items]
Revenues		55	32	142	77
Oncology [Member] | Biopharma [Member] | Braftovi [Member]
Revenue from External Customer [Line Items]
Revenues		42	18	116	18
Oncology [Member] | Biopharma [Member] | Mektovi [Member]
Revenue from External Customer [Line Items]
Revenues		34	19	103	19
Oncology [Member] | Biopharma [Member] | Ruxience [Member]
Revenue from External Customer [Line Items]
Revenues	[1]	59	0	78	0
Oncology [Member] | Biopharma [Member] | All other Oncology [Member]
Revenue from External Customer [Line Items]
Revenues		217	125	522	342
Hospital [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[3],[4]	1,728	1,840	5,535	5,505
Hospital [Member] | Biopharma [Member] | Sulperazon [Member]
Revenue from External Customer [Line Items]
Revenues	[3],[4]	143	163	432	505
Hospital [Member] | Biopharma [Member] | Medrol [Member]
Revenue from External Customer [Line Items]
Revenues	[3],[4]	87	109	295	348
Hospital [Member] | Biopharma [Member] | Zithromax [Member]
Revenue from External Customer [Line Items]
Revenues	[3],[4]	25	77	218	254
Hospital [Member] | Biopharma [Member] | Precedex [Member]
Revenue from External Customer [Line Items]
Revenues	[3],[4]	55	36	211	116
Hospital [Member] | Biopharma [Member] | Vfend [Member]
Revenue from External Customer [Line Items]
Revenues	[3],[4]	52	87	201	265
Hospital [Member] | Biopharma [Member] | Panzyga [Member]
Revenue from External Customer [Line Items]
Revenues	[3],[4]	62	46	199	107
Hospital [Member] | Biopharma [Member] | Fragmin [Member]
Revenue from External Customer [Line Items]
Revenues	[3],[4]	60	62	178	185
Hospital [Member] | Biopharma [Member] | Zyvox [Member]
Revenue from External Customer [Line Items]
Revenues	[3],[4]	51	61	176	195
Hospital [Member] | Biopharma [Member] | Pfizer CentreOne [Member]
Revenue from External Customer [Line Items]
Revenues	[3],[4],[5]	242	176	618	556
Hospital [Member] | Biopharma [Member] | All other Anti-infectives [Member]
Revenue from External Customer [Line Items]
Revenues	[3],[4]	384	434	1,195	1,260
Hospital [Member] | Biopharma [Member] | All other Hospital [Member]
Revenue from External Customer [Line Items]
Revenues	[3],[4]	568	589	1,813	1,713
Vaccines [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		1,717	1,808	4,574	4,795
Vaccines [Member] | Biopharma [Member] | Prevnar 13/Prevenar 13 [Member]
Revenue from External Customer [Line Items]
Revenues		1,534	1,603	4,100	4,268
Vaccines [Member] | Biopharma [Member] | Nimenrix [Member]
Revenue from External Customer [Line Items]
Revenues		50	52	180	159
Vaccines [Member] | Biopharma [Member] | FSME/IMMUN-TicoVac [Member]
Revenue from External Customer [Line Items]
Revenues		77	64	170	197
Vaccines [Member] | Biopharma [Member] | All other Vaccines [Member]
Revenue from External Customer [Line Items]
Revenues		56	89	124	171
Inflammation and Immunology (I&I) [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		1,173	1,226	3,299	3,482
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | Xeljanz [Member]
Revenue from External Customer [Line Items]
Revenues		654	599	1,741	1,634
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | Enbrel (Outside the U.S. and Canada) [Member]
Revenue from External Customer [Line Items]
Revenues		321	415	1,005	1,285
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | Inflectra/Remsima [Member]
Revenue from External Customer [Line Items]
Revenues	[1]	162	155	471	446
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | All other I & I [Member]
Revenue from External Customer [Line Items]
Revenues		35	58	83	116
Rare Disease [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		752	601	2,071	1,592
Rare Disease [Member] | Biopharma [Member] | Vyndaqel/Vyndamax [Member]
Revenue from External Customer [Line Items]
Revenues		351	156	859	259
Rare Disease [Member] | Biopharma [Member] | BeneFIX [Member]
Revenue from External Customer [Line Items]
Revenues		107	125	337	372
Rare Disease [Member] | Biopharma [Member] | Genotropin [Member]
Revenue from External Customer [Line Items]
Revenues		107	124	316	357
Rare Disease [Member] | Biopharma [Member] | ReFacto AF/Xyntha [Member]
Revenue from External Customer [Line Items]
Revenues		92	104	272	319
Rare Disease [Member] | Biopharma [Member] | Somavert [Member]
Revenue from External Customer [Line Items]
Revenues		67	64	198	192
Rare Disease [Member] | Biopharma [Member] | All other Rare Disease [Member]
Revenue from External Customer [Line Items]
Revenues		27	28	89	94
Upjohn [Member] | Upjohn [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	1,916	2,351	5,944	8,535
Upjohn [Member] | Upjohn [Member] | Lipitor [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	356	476	1,191	1,506
Upjohn [Member] | Upjohn [Member] | Lyrica [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	352	527	1,058	2,888
Upjohn [Member] | Upjohn [Member] | Norvasc [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	183	219	601	735
Upjohn [Member] | Upjohn [Member] | Celebrex [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	133	179	428	526
Upjohn [Member] | Upjohn [Member] | Viagra [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	121	120	342	379
Upjohn [Member] | Upjohn [Member] | Effexor [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	80	80	242	242
Upjohn [Member] | Upjohn [Member] | Zoloft [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	76	74	233	217
Upjohn [Member] | Upjohn [Member] | EpiPen [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	58	74	194	197
Upjohn [Member] | Upjohn [Member] | Xalatan/Xalacom [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	62	68	188	201
Upjohn [Member] | Upjohn [Member] | Xanax [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	55	50	149	147
Upjohn [Member] | Upjohn [Member] | All other Upjohn [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	442	485	1,317	1,496
Consumer Healthcare [Member] | Consumer Healthcare [Member]
Revenue from External Customer [Line Items]
Revenues	[6]	$ 0	$ 377	$ 0	$ 2,098

[1] Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima, Retacrit and Ruxience.

[2] Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals.

[3] Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan). As a result, revenues associated with our Meridian subsidiary, except for product revenues for EpiPen sold in Canada, and Mylan-Japan, are reported in our Upjohn business beginning in the first quarter of 2020. We have reclassified revenues associated with our Meridian subsidiary and Mylan-Japan from the Hospital and Internal Medicine categories to the Upjohn business to conform 2019 product revenues to the current presentation.

[4] Hospital is a business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. Hospital also includes Pfizer CentreOne(d). All other Hospital primarily includes revenues from legacy Sterile Injectables Pharmaceuticals (SIP) products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in “All other Anti-infectives”.

[5] Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements.

[6] On July 31, 2019, Pfizer’s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK’s consumer healthcare business to form a new consumer healthcare joint venture. See Note 2B.